Stock 688513 CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Chengdu Easton Biopharmaceuticals Co., Ltd.

Equities

688513

CNE100004397

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
58.02 CNY -0.99% Intraday chart for Chengdu Easton Biopharmaceuticals Co., Ltd. -5.32% -9.03%
04-22 Chengdu Easton Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-16 Easton Biopharma's Unit Gets Nod to Market Bisoprolol Amlodipine Tablets MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The company's profit outlook over the next few years is a strong asset.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • The company benefits from high valuations in earnings multiples.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. Stock Chengdu Easton Biopharmaceuticals Co., Ltd.
-9.03% 966M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.09% 694B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 593B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.34% 371B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.39% 290B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 239B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 209B
A+
NOVARTIS AG Stock Novartis AG
+10.02% 209B
B-
AMGEN INC. Stock Amgen Inc.
+8.49% 169B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. 688513 Stock
  4. Ratings Chengdu Easton Biopharmaceuticals Co., Ltd.